Nutlin-3-PLGA NPs have also been formulated, via nanoprecipitation, and conjugated to the human monoclonal antibody against CD-138/Syndecan-1 (anti-Syndecan-1) to target primary effusion lymphoma. Here, SDC1 is linked to primary effusion lymphoma.